contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


abliva-ab-interim-report-january-september-2022

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Abliva

Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseasesThird quarter summary Important events third...

<div class="mfn-preamble">Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases</div><div class="mfn-body">Third quarter summary Important events third quarter (Jul - Sep 2022)<ul><li>Abliva received additional regulatory approvals to start the FALCON study with KL1333.</li><li>Abliva participated in World Mitochondrial Disease Week 2022 through videos focused on increasing the understanding of the community to rare disease development, and more specifically to the development of new therapies for primary mitochondrial diseases. The videos are available on Abliva’s website.</li></ul>Financial informationJuly-September 2022*<ul><li>Net revenues: SEK 31,000 (85,000)</li><li>Other operating income: SEK 651,000 (0,000)</li><li>Loss before tax: SEK 25,124,000 (34,854,000)</li><li>Loss per share before dilution: SEK 0.04 (0.09)</li><li>Diluted loss per share: SEK 0.04 (0.09)</li></ul>January-September 2022*<ul><li>Net revenues: SEK 31,000 (103,000)</li><li>Other operating income: SEK 212,000 (0,000)</li><li>Loss before tax: SEK 67,688,000 (86,624,000)</li><li>Loss per share before dilution: SEK 0.11 (0.24)</li><li>Diluted loss per share: SEK 0.11 (0.24)</li></ul>* APM Alternative performance measures, see definition on page 20.The complete Interim report is available for download below and through Abliva's website <a rel="nofollow noopener" href="http://www.abliva.com/">www.abliva.com</a>.</div><div class="mfn-footer mfn-d318f2261daa">For more information, please contact:<hr>Catharina Johansson, Deputy CEO, CFO&nbsp;&amp; VP Investor Relations +46 (0)46-275 62 21, <a rel="nofollow noopener" href="mailto:ir@abliva.com">ir@abliva.com</a>Abliva AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) <a rel="nofollow noopener" href="mailto:info@abliva.com">info@abliva.com</a>,&nbsp;<a rel="nofollow noopener" href="http://www.abliva.com">www.abliva.com</a>Subscribe to our news:&nbsp;<a rel="nofollow noopener" href="https://abliva.com/posts/news-subscription/">https://abliva.com/posts/news-subscription/</a> Follow&nbsp;us&nbsp;on LinkedIn:&nbsp;<a rel="nofollow noopener" href="https://www.linkedin.com/company/abliva">https://www.linkedin.com/company/abliva</a> Subscribe&nbsp;to&nbsp;our YouTube&nbsp;channel:&nbsp;<a rel="nofollow noopener" href="https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg">https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg</a></div><div class="mfn-footer mfn-72682e636cb1">Abliva – Delivering mitochondrial health<hr>Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is entering late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="nofollow noopener" href="https://storage.mfn.se/8c40cee7-32a7-4a54-bf60-5cf0de896f19/abliva-q3-2022-en-final.pdf" class="mfn-primary">Abliva Q3 2022 EN Final</a></div>